| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/04/2013 | CA2228667C Antagonists of the oncogenic activity of the protein mdm2, and use thereof in the treatment of cancers |
| 06/02/2013 | CA2772180A1 Anti-npy and pyy antibodies and uses thereof |
| 05/30/2013 | WO2013078393A1 Treating bladder cancer patients and identifying bladder cancer patients responsive to treatment |
| 05/30/2013 | WO2013078392A1 Methods and compositions involving induced senescent cells for cancer treatment |
| 05/30/2013 | WO2013078377A1 Anti-cd98 antibodies and methods of use thereof |
| 05/30/2013 | WO2013078271A1 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| 05/30/2013 | WO2013078254A1 Bicyclic heteroaryl derivatives as kinase inhibitors |
| 05/30/2013 | WO2013078126A1 Thienopyrimidine inhibitors of atypical protein kinase c |
| 05/30/2013 | WO2013078123A1 Heterocyclic inhibitors of glutaminase |
| 05/30/2013 | WO2013077675A1 Method for overcoming tolerance to targeted anti-cancer agent |
| 05/30/2013 | WO2013077618A1 Pharmaceutical composition containing anti-kiaa1114 antibody as active ingredient for preventing or treating cancer induced by kiaa1114 over-expression |
| 05/30/2013 | WO2013077534A1 Protein p14 with anti-cancer and anti-allergy activity and pharmaceutical composition comprising the same |
| 05/30/2013 | WO2013077458A1 Anti-human trop-2 antibody exhibiting antitumor activity in vivo |
| 05/30/2013 | WO2013077446A1 Single-stranded nucleic acid molecule for regulating expression of gene |
| 05/30/2013 | WO2013077228A1 Impdh inhibitor having microrna as active component |
| 05/30/2013 | WO2013076516A1 1,4- dihydropyridine derivatives with hsp modulating activity |
| 05/30/2013 | WO2013076374A1 Recombinant serotype 5 (ac!5) adenoviral vectors |
| 05/30/2013 | WO2013076275A1 Androgen receptor ligands |
| 05/30/2013 | WO2013076183A1 Combination therapy using anti - cd20 antibody and human il-15 |
| 05/30/2013 | WO2013076090A1 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| 05/30/2013 | WO2013076063A1 Novel pyrrolidine derivatives as inhibitors of cathepsin |
| 05/30/2013 | WO2013075785A1 3-cyanaryl-1h-pyrazolo[2.3-b]pyridine derivatives |
| 05/30/2013 | WO2013075607A1 Novel use of chlorogenic acid against cancer |
| 05/30/2013 | WO2013075600A1 Polyethylene glycol-modified integrin blocker hm-3 and use thereof |
| 05/30/2013 | WO2013075553A1 Superantigen fusion protein targeting cancer and preparation method and use thereof |
| 05/30/2013 | WO2013075394A1 Drug carrier with chelating composite micell and use thereof |
| 05/30/2013 | WO2013075391A1 Electromagnetic therapeutic apparatus and supporting physiotherapy liquid thereof |
| 05/30/2013 | WO2013075382A1 Anti human her2 monoclonal antibody |
| 05/30/2013 | WO2013075237A1 Mutations of histone proteins associated with proliferative disorders |
| 05/30/2013 | WO2013075233A1 Method for treating brain cancer |
| 05/30/2013 | WO2013075199A1 Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
| 05/30/2013 | WO2013075186A1 Polymeric nanospheres coated with chitosan folate and use of the same |
| 05/30/2013 | WO2013056245A3 Stearate compounds |
| 05/30/2013 | WO2013052772A3 Anti-human sema4a antibodies useful to treat disease |
| 05/30/2013 | WO2013049280A3 Sphingosine analogs, compositions, and methods related thereto |
| 05/30/2013 | WO2013043933A3 Cd27l antigen binding proteins |
| 05/30/2013 | WO2013025074A3 Anticancer or antioxidant composition containing quamoclit pennata extract or compound derived from quamoclit pennata extract |
| 05/30/2013 | WO2013025004A3 Pharmaceutical composition for preventing or treating cancer comprising radix lithospermi seu arnebiae extract as an active ingredient |
| 05/30/2013 | WO2013022092A9 Heptamer-type small guide nucleic acid capable of inducing apoptosis of human hematologic cancer cells |
| 05/30/2013 | WO2012059725A8 Peg or peg block copolymers for treating colorectal cancer |
| 05/30/2013 | US20130137772 Hydroxypolyamine salts |
| 05/30/2013 | US20130137758 Akt activity specifically inhibiting polypeptide |
| 05/30/2013 | US20130136812 Alcohol extract of dehulled adlay seeds for treating gastric ulcer and/or stomach cancer |
| 05/30/2013 | US20130136787 Liposomal Camptothecins and Uses Thereof |
| 05/30/2013 | US20130136714 Functionalized polymer nanoparticles and the pharmaceutical use thereof |
| 05/30/2013 | CA2856873A1 Anti-cd98 antibodies and methods of use thereof |
| 05/30/2013 | CA2856803A1 Enhanced treatment regimens using mtor inhibitors |
| 05/30/2013 | CA2856759A1 3-phenyl-isoquinolin-1(2h)-one derivatives as parp-1 inhibitors |
| 05/30/2013 | CA2856501A1 A drug carrier with chelating complex micelles and the application thereof |
| 05/30/2013 | CA2856411A1 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate |
| 05/30/2013 | CA2856386A1 Heterocyclic inhibitors of glutaminase |
| 05/30/2013 | CA2856379A1 Small molecule enhancer for dendritic cell cancer vaccines |
| 05/30/2013 | CA2856357A1 3-cyanoaryl-1h-pyrrolo[2,3-b]pyridine derivatives |
| 05/30/2013 | CA2856297A1 Binding molecules specific for her3 and uses thereof |
| 05/30/2013 | CA2855980A1 Pyridone amides and analogs exhibiting anti-cancer and anti-proliferative activities |
| 05/30/2013 | CA2855699A1 Anti-human trop-2 antibody having an antitumor activity in vivo |
| 05/30/2013 | CA2855446A1 Thienopyrimidine inhibitors of atypical protein kinase c |
| 05/30/2013 | CA2854569A1 Novel pyrrolidine derivatives as inhibitors of cathepsin |
| 05/30/2013 | CA2854255A1 Mutations of histone proteins associated with proliferative disorders |
| 05/30/2013 | CA2854252A1 1,4-dihydropyridine derivatives with hsp modulating activity |
| 05/30/2013 | CA2851210A1 Combination therapy using anti-cd20 antibody and human il-15 |
| 05/30/2013 | CA2846496A1 Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
| 05/29/2013 | EP2597105A1 A conjugate comprising angiostatin or its fragment, the method for producing the conjugate and use thereof |
| 05/29/2013 | EP2597104A1 Antibodies against human TWEAK and uses thereof |
| 05/29/2013 | EP2597098A1 (7h-pyrrolo [2, 3-d] pyrimidin-4-yl) -piperazines as kinase inhibitors for the treatment of cancer and inflammation |
| 05/29/2013 | EP2597093A1 Benzofuranone compound and pharmaceutical composition containing same |
| 05/29/2013 | EP2597086A1 Cyclic n,n'-diarylthioureas and n,n'-diarylureas as androgen receptor antagonists, anti-cancer agent, method for producing and using same |
| 05/29/2013 | EP2597084A1 N-hydroxyformamide derivative and pharmaceutical containing same |
| 05/29/2013 | EP2596804A2 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 05/29/2013 | EP2596803A2 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 05/29/2013 | EP2596801A1 Methods for treating cancer with mva |
| 05/29/2013 | EP2596795A1 Methods of administering n-(5-tert-butyl-isoxazol-3-yl)-n?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease |
| 05/29/2013 | EP2596790A1 Pim kinase inhibitors and methods of their use |
| 05/29/2013 | EP2596366A1 Combination therapy with mdm2 and efgr inhibitors |
| 05/29/2013 | EP2596025A1 Methods for cancer management targeting co-029 |
| 05/29/2013 | EP2596008A1 Tubulysin analogues |
| 05/29/2013 | EP2595991A2 METHODS AND COMPOSITIONS FOR INHIBITING THE NUCLEAR FACTOR kB PATHWAY |
| 05/29/2013 | EP2595987A1 New aminopyrazoloquinazolines |
| 05/29/2013 | EP2595982A1 Protein kinase c inhibitors and uses thereof |
| 05/29/2013 | EP2595972A1 Tricyclic lactones for treatment of cancer |
| 05/29/2013 | EP2595964A1 Pyrimidine compounds as inhibitors of protein kinases ikk epsilon and/or tbk-1, processes for their preparation, and pharmaceutical compositions containing them |
| 05/29/2013 | EP2595660A2 Bendamustine anionic-catioinic cyclopolysaccharide compositions |
| 05/29/2013 | EP2595659A1 Method, device and system for targetted cell lysis |
| 05/29/2013 | EP2595646A2 Bhlh proteins and their use as drugs |
| 05/29/2013 | EP2595629A1 Pure erlotinib |
| 05/29/2013 | EP2595628A1 Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| 05/29/2013 | EP2595624A2 Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects |
| 05/29/2013 | EP2595622A1 Medicaments based on dinuclear arene ruthenium complexes comprising bridging thiolato, selenolato or alkoxo ligands |
| 05/29/2013 | EP2595619A1 Methods of treating metastatic breast cancer with 4-iodo-3-nitrobenzamide and irinotecan |
| 05/29/2013 | EP2595618A1 Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| 05/29/2013 | EP2595616A2 Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| 05/29/2013 | EP2595615A1 Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
| 05/29/2013 | CN1911965B Binding domain-immunoglobulin fusion proteins |
| 05/29/2013 | CN1829740B Connective tissue growth factor antibodies |
| 05/29/2013 | CN1705491B Optimized Fc variants and methods for their generation |
| 05/29/2013 | CN1582165B Antibodies to CD40 |
| 05/29/2013 | CN1525866B Treatment using neublastin polypeptides |
| 05/29/2013 | CN103124743A RON binding constructs and methods of use thereof |
| 05/29/2013 | CN103124731A Fused heteroaryls and their uses |
| 05/29/2013 | CN103124729A Pharmaceutically active compounds as Axl inhibitors |